medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2022, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2022; 38 (2)

Venous thromboembolic disease in hematologic malignancies: a preventive approach

López SA, Torres IW, Cruz RJ

Language: Spanish
References: 55
Page: 1-21
PDF size: 541.54 Kb.


ABSTRACT

Introduction: Venous thromboembolic disease is a frequent complication in hematologic malignancies with incidence similar to that observed in solid tumors with high thrombotic risk.
Objective: To describe the influence of risk factors and biomarkers of venous thromboembolic disease associated with hematologic malignancies and their application in the design of risk assessment models for the prevention of this disease.
Methods: An exhaustive review was carried out in the specialized literature of articles published on the subject using the following databases: PubMed, SciELO, ScienceDirect, Medline and the academic Google search engine.
Analysis and synthesis of the information: Multiple risk factors for the occurrence of venous thromboembolism have been described in patients with hematologic malignancies: patient-related, disease-related, treatment-related and molecular, as well as biomarkers of risk. Based on these, several investigations have been developed to elaborate and validate predictive venous thromboembolism models to guide risk stratification and prophylactic treatment of venous thromboembolic disease in hematologic malignancies, although they are still insufficient. Lymphomas and multiple myeloma have more research in this area than other hematologic malignancies.
Conclusion: There is a need to design new risk models and validate existing ones in a larger number of cases, as well as to develop prospective studies in patients at risk of thromboembolic events and hematologic malignancies, to carry out a personalized primary prevention strategy with thromboprophylaxis stratification.


REFERENCES

  1. Salvador C, Segura A. Modelos predictivos de riesgo de enfermedad tromboembólica venosa. Madrid: SEOM; 2019. [acceso 25/04/2021]. Disponible en: https://seom.org/images/Modelos_predictivos_de_riesgo_ETV.pdf

  2. ISTH. Día Mundial de la Trombosis/ Tromboembolia venosa (TEV). 2022. [acceso 25/04/2021].Disponible en: https://es.worldthrombosisday.org/issue/vte/2.

  3. Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. The Oncologist. 2017;22(2):199-207. DOI: https://10.1634/theoncologist.2016-02143.

  4. Lyman GH, Culakova E, Poniewierski MS, Kuderer NM, et al. Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer. Thromb Res. 2018;164 (Suppl 1):S112-8. DOI: https://10.1016/j.thromres.2018.01.0284.

  5. Rodríguez C, Rodríguez L, Figueroa G, Gazitúa R, Conte G. Tromboprofilaxis farmacológica en pacientes oncológicos quirúrgicos en el Hospital Clínico de la Universidad de Chile. Rev Hosp Clín Univ Chile. 2015;26:5-11.

  6. Riondino S, Ferroni P, Zanzotto FM, Roselli M, Guadagni F. Predicting VTE in Cancer Patients; Candidate Biomarkers and Risk Assesment Models. Cancers (Basel). 2019;11(1):95. DOI: https://10.3390/cancers110100956.

  7. Kekre N, Connors J.M. Venous thromboembolism incidence in hematologic malignancies. Blood Rev. 2019;33:24-32. DOI: https://10.1016/j.blre.2018.06.0027.

  8. Horowitz NA, Brenner B. Thrombosis in hematological malignancies: mechanisms and implications. Thromb Res. 2020;191 Suppl 1:S58-S62. DOI: https://10.1016/S0049-3848(20)30398-48.

  9. Mulder FI, Van Es N. Clinical prediction scores for venous thromboembolism in hematological malignancy. Hemasphere. 2018;2(Suppl):37-9. DOI: https://10.1097/HS9.00000000000000729.

  10. Annibali O, Napolitano M, Avvisati G, Siragusa S. Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature. Crit Rev Oncol Hematol. 2018;124:41-50. DOI: https://10.1016/j.critrevonc.2018.02.00310.

  11. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI. et al. Venous Thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38(5):496-520 DOI: https://10.1200/JCO.19.0146111.

  12. Mosaad M. Hassan Elnaem M, Cheema E, Ibrahim I, Ab Rahman J. Naila A. et al. Cancer-Associated Thrombosis: A Clinical Scoping Review of the Risk Assessment Models Across Solid Tumours and Haematological Malignancies. Int J Gen Med. 2021;14:3881-3897. DOI: https://10.2147/IJGM.S32049212.

  13. Mahajan A, Wun T. Biomarkers of Cancer-Associated Thromboembolism. In Thrombosis and Hemostasis in Cancer. Cancer Treat Res. 2019;179:69-85. DOI: https://10.1007/978-3-030-20315-3_513.

  14. Lazar S, Goldfinger LE. Platelets and extracellular vesicles and their cross talk with cancer. Blood. 2021;137(23):3192-3200. DOI: https://10.1182/blood.201900411914.

  15. Lee JO, Lee JY, Kim JW, Kim SH, Kim YJ, Lee KW, et al. Incidence and predictors of venous thromboembolism in medically ill hospitalized elderly cancer patients: a prospective observational study. Support Care Cancer. 2019;27(7):2507-15. DOI: https://10.1007/s00520-018-4537-y15.

  16. Muñoz AJ, Pérez S, Ortega L, Ruíz M, Viñuela MC, Aparicio I, et al. Pharmacological cancer treatment and venous thromboembolism risk. Eur Heart J Suppl. 2020;22(Suppl C):C2-C14. DOI: https://10.1093/eurheartj/suaa00416.

  17. Guy JB, Bertoletti L, Magné N, Rancoule C, Mahé I, Font C, et al. RIETE investigators. Venous thromboembolism in radiation therapy cancer patients: Findings from the RIETE registry. Crit Rev Oncol Hematol. 2017;113:83-9. DOI: https://10.1016/j.critrevonc.2017.03.00617.

  18. Falanga A, Jokiranta S, Hill A, Giovanni P. Thrombosis in haematological disorders: tailored management approaches. Summary of presentations from the Alexion-supported satellite symposium held at the 20 th Congress of the European. EMJ Hema. 2015;3(1):38-46.

  19. Khamal N, Bociek RG, Chen B, Vose JM, Armitage JO, Bierman PJ, et al. Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia. Am J Hematol. 2016; 91(11):468-72. Am J Hematol. 2016;91(11):E468-72. DOI: https://10.1002/ajh.2452619.

  20. Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017 Sep 28;130(13):1499-1506. DOI: https://10.1182/blood-2017-03-74321120.

  21. Griffin M, Munir T. Management of thrombosis in paroxysmal nocturnal hemoglobinuria: a clinician's guide. Ther Adv Hematol. 2017;8(3):119-26. DOI: https://10.1177/204062071668174821.

  22. De Stefano V, Finazzi G, Barbui T. Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms. Blood Cancer J. 2018;8(7):65. DOI: https://10.1038/s41408-018-0101-822.

  23. Napolitano M, Valore L, Malato A, Saccullo G, Vetro C, Mitra ME et al. Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study. Leuk Lymphoma. 2016;57(1):116-9. DOI: https://10.3109/10428194.2015.104686423.

  24. Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer - associated thrombosis: An overview of mechanisms, risk factors, and treatment. Cancers (Basel). 2018;10(10):380. DOI: https://10.3390/cancers1010038024.

  25. Del Principe MI, Del Principe D, Venditti A. Thrombosis in adult patients with acute leukemia. Curr Opin Oncol. 2017;29(6):448-54. DOI: https://10.1097/CCO.000000000000040225.

  26. Hohaus S, Bartolomei F, Cuccaro A, Maiolo E, Alma E, D'alò F, et al. Venous thromboembolism in lymphoma: risk stratification and antithrombotic prophylaxis. Cancers (Basel). 2020;12(5):1291. DOI: https://10.3390/cancers1205129126.

  27. Kirkizlar O, Alp kirkizlar T, Umit EG, Asker I, Baysal M, Bas V, et al. The incidence of venous thromboembolism and impact on survival in Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20(8):542-7. DOI: https://10.1016/j.clml.2020.02.02127.

  28. Li W, García D, Cornell F, Gailani D, Laubach J, Maglio ME, et al. Cardiovascular and Thrombotic Complications of Novel Multiple Myeloma Therapies: A review. JAMA Oncol. 2017;3(7):980-8. DOI: https://10.1001/jamaoncol.2016.335028.

  29. Hashimoto Y, Nakamae H, Tanaka T, Omura H, Horiuchi M, Yoshimura T, et al. Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia. Eur J Haematol. 2018;101(4):508-13. DOI: https://10.1111/ejh.1313629.

  30. Carestia A, Kaufman T, Rivadeneyra L, Landoni VI, Pozner RG, Negrotto S, et al. Mediators and molecular pathways involved in the regulation of neutrophil extracellular trap formation mediated by activated platelets. J Leukoc Biol. 2016;99(1):153-62. DOI: https://10.1189/jlb.3A0415-161R30.

  31. Oppelt P, Betbadal A, Nayak L. Approach to chemotherapy-associated thrombosis. Vasc Med. 2015;20(2):153-61. DOI: https://10.1177/1358863X1456870531.

  32. Mukai M, Oka T. Mechanism and management of cancer-associated thrombosis. J Cardiol. 2018 Aug;72(2):89-93. DOI: https://10.1016/j.jjcc.2018.02.01132.

  33. Zoppellaro G, Veronese N, Granziera S, Gobbi L, Stubbs B, Cohen AT. Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin use. Semin Hematol. 2018;55(4):182-4. DOI: https://10.1053/j.seminhematol.2017.08.00233.

  34. Leung C, Heal A, Perera M, Pretorius C. A systematic review of patient- related risk factors for catheter-related thrombosis. J Thromb Thrombolysis. 2015;40(3):363-73. DOI: https://10.1007/s11239-015-1175-934.

  35. Streiff MB, Holmstrom B, Ashrani A, Bockenstedt PL, Chesney C, Eby C, et al. Cancer-associated venous thromboembolic disease Version 1 2015. J Natl Compr Canc Netw. 2015;13(9):1079-95. DOI: https://10.6004/jnccn.2015.013335.

  36. Chennakrishnaiah S, Meehan B D, Asti E, Montermini L, Lee TH, Karatzas N, et al. Leukocytes as a reservoir of circulating oncogenic DNA and regulatory targets of tumor-derived extracellular vesicles. J Thromb Haemost. 2018;16(9):1800-13. DOI: https://10.1111/jth.1422236.

  37. Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018;18(3):139-147. DOI: 10.1038/nrc.2017.11737. .

  38. Schorling RM, Pfrepper C, Golombek T, Cella C A, Muñoz-Unceta N, Siegemund R, et al. Evaluation of biomarkers for the prediction of venous thromboembolism in ambulatory cancer patients. Oncol Res Treat. 2020;43(9):414-27. DOI: https://10.1159/00050827138.

  39. Linkins LA, Takach Lapner S. Review of D-dimer testing: Good, Bad, and Ugly. nt J Lab Hematol. 2017;39 Suppl 1:98-103. DOI: https://10.1111/ijlh.1266539.

  40. Park K, Ryoo BY, Ryu MH, Park SR, Kang MJ, Kim JH, et al. Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: A prospective study. World J Gastrointest Oncol. 2017;9(4):176-83. DOI: https://10.4251/wjgo.v9.i4.17640.

  41. Ghozlan MF, Osman AA, Mahmoud HM, Eissa DG, Abuelela S. Comprehensive study on laboratory biomarkers for prediction and diagnosis of deep venous thrombosis. Blood Coagul Fibrinolysis.2015;26(3):255-60. DOI: https://10.1097/MBC.000000000000016441.

  42. Fricke A, Ullrich PV, Cimniak AFV, Becherer C, Follo M, Heinz J, et al. Levels of activated platelet-derived microvesicles in patients with soft tissue sarcoma correlate with an increased risk of venous thromboembolism. BMC Cancer. 2017;17(1):527. DOI: https://10.1186/s12885-017-3515-y42.

  43. Hisada Y, Mackman N. Tissue Factor and extracellular vesicles: activation of coagulation and impact on survival in cancer. Cancers (Basel). 2021;13(15):3839. DOI: https://10.3390/cancers1315383943.

  44. Ay C, Vormittag R, Dunkler D, Simanek R, Chiriac AL, Drach J, et al. D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from de Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009;27(25):4124-9. DOI: https://10.1200/JCO.2008.21.775244.

  45. Jenkins PV, Rawley O, Smith OP, O'Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol. 2012;157(6):653-63. DOI: https://10.1111/j.1365-2141.2012.09134.x45.

  46. Reitter EM, Ay C, Kaider A, Pirker R, Zielinski C, Zlabinger G, Pabinger I. Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients. Clin Exper Immunol. 2014;177(1):253-60. DOI: https://10.1111/cei.1230846.

  47. Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, Asensio-Cruz MI, Blasco-Esquivias I, Sanchez-Lopez V, et al. D-dimer and high sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer associated thrombosis. Br J Cancer. 2018;119(8):915-21. DOI: https://10.1038/s41416-018-0269-547.

  48. Plantureux L, Crescence L, Dignat-George F, Panicot-Dubois L, Dubois C. Effects of platelets on cancer progression. Thromb Res. 2018;164(Suppl 1):S40-7. DOI: https://10.1016/j.thromres.2018.01.03548.

  49. Tham T, Rahman L, Persaud C, Olson C, Costantino P. Venous thromboembolism risk in head and neck cancer: Significance of the preoperative platelet-to-lymphocyte ratio. Otolaryngol Head Neck Surg. 2018;159(1):85-91. DOI: https://10.1177/019459981875685149.

  50. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-7. DOI: https://10.1182/blood-2007-10-11632750.

  51. Grilz E, Posch F, Königsbrügge O, Schwarzinger I, Lang IM, Marosi C, et al. Association of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with the risk of thromboembolism and mortality in patients with cancer. Thromb Haemost. 2018;118(11):1875-84. DOI: https://10.1055/s-0038-167340151.

  52. Guadagni F, Riondino S, Formica V, Del Monte G, Morelli AM, Lucchetti J, et al. Clinical significance of glycemic parameters on venous thromboembolism risk prediction in gastrointestinal cancer. World J Gastroenterol. 2017;23(28):5187-95. DOI: https://10.3748/wjg.v23.i28.518752.

  53. Ruiz Hidalgo D, Benito Vales S. Desarrollo y validación de un modelo predictivo de mortalidad a corto plazo en ancianos ingresados por patología médica [Tesis doctoral]. Barcelona: Universidad Autónoma de Barcelona; 2016. [acceso 25/04/2021]. Disponible en: https://ddd.uab.cat/pub/tesis/2016/hdl_10803_399340/drh1de1.pdf53.

  54. Khorana AA, Francis CW. Risk prediction of cancer-associated thrombosis: appraising the first decade and developing the future. Thromb Res. 2018;164(Suppl. 1):S70-6. DOI: https://10.1016/j.thromres.2018.01.03654.

  55. Sanfilippo KM, Wang T-F, Luo S, Thomas T S, Carson K R, Keller J W, et al. Predictive ability of the Khorana score for venous thromboembolism (VTE) in multiple myeloma (MM). J Clin Med. 2021;10(16):3536. DOI: https://10.3390/jcm1016353655.




2020     |     www.medigraphic.com